Use of EGF A61G polymorphism to predict overall survival in a phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205) Meeting Abstract
| Authors: | Labonte, M. J.; Goldman, B. H.; Zhang, W.; Blanke, C. D.; Philip, P. A.; Wong, R.; O'Reilly, E. M.; Benedetti, J. K.; Lenz, H. J. |
| Abstract Title: | Use of EGF A61G polymorphism to predict overall survival in a phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205) |
| Meeting Title: | 2012 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2012 Jan 19-21 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-02-01 |
| Language: | English |
| ACCESSION: | WOS:000209849300203 |
| DOI: | 10.1200/jco.2012.30.4_suppl.203 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 203 -- Source: Wos |
